In a preclinical model of breast cancer using an ER+ cell line (MCF-7), the overexpression of FGFR1 causes a resistance to treatment with fulvestrant and a CDK4/6 inhibitor, either palbociclib or ribociclib [80]. This evidence concerns the gene FGFR1 and breast carcinoma.